ABSTRACT
Proliferating mammalian cells use glutamine as a source of nitrogen and as a key anaplerotic source to provide metabolites to the tricarboxylic acid cycle (TCA) for biosynthesis. Recently, mammalian target of rapamycin complex 1 (mTORC1) activation has been correlated with increased nutrient uptake and metabolism, but no molecular connection to glutaminolysis has been reported. Here, we show that mTORC1 promotes glutamine anaplerosis by activating glutamate dehydrogenase (GDH). This regulation requires transcriptional repression of SIRT4, the mitochondrial-localized sirtuin that inhibits GDH. Mechanistically, mTORC1 represses SIRT4 by promoting the proteasome-mediated destabilization of cAMP-responsive element binding 2 (CREB2). Thus, a relationship between mTORC1, SIRT4, and cancer is suggested by our findings. Indeed, SIRT4 expression is reduced in human cancer, and its overexpression reduces cell proliferation, transformation, and tumor development. Finally, our data indicate that targeting nutrient metabolism in energy-addicted cancers with high mTORC1 signaling may be an effective therapeutic approach.
Subject(s)
Glutamine/metabolism , Mitochondrial Proteins/metabolism , Neoplasms/metabolism , Sirtuins/metabolism , Activating Transcription Factors/metabolism , Animals , Cell Proliferation , Embryo, Mammalian/cytology , Energy Metabolism , Glutamate Dehydrogenase/metabolism , Humans , Mechanistic Target of Rapamycin Complex 1 , Mice , Multiprotein Complexes , Neoplasm Transplantation , Neoplasms/pathology , TOR Serine-Threonine Kinases/metabolism , Transcription, Genetic , Transplantation, Heterologous , Tuberous Sclerosis Complex 2 Protein , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism , UbiquitinationABSTRACT
The metabolism of glucose and glutamine, primary carbon sources utilized by mitochondria to generate energy and macromolecules for cell growth, is directly regulated by mTORC1. We show that glucose and glutamine, by supplying carbons to the TCA cycle to produce ATP, positively feed back to mTORC1 through an AMPK-, TSC1/2-, and Rag-independent mechanism by regulating mTORC1 assembly and its lysosomal localization. We discovered that the ATP-dependent TTT-RUVBL1/2 complex was disassembled and repressed by energy depletion, resulting in its decreased interaction with mTOR. The TTT-RUVBL complex was necessary for the interaction between mTORC1 and Rag and formation of mTORC1 obligate dimers. In cancer tissues, TTT-RUVBL complex mRNAs were elevated and positively correlated with transcripts encoding proteins of anabolic metabolism and mitochondrial function-all mTORC1-regulated processes. Thus, the TTT-RUVBL1/2 complex responds to the cell's metabolic state, directly regulating the functional assembly of mTORC1 and indirectly controlling the nutrient signal from Rags to mTORC1.
Subject(s)
Energy Metabolism , Lysosomes/metabolism , Proteins/metabolism , Stress, Physiological , ATPases Associated with Diverse Cellular Activities , Adenosine Triphosphate/metabolism , Adenylate Kinase/metabolism , Animals , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Carcinoma/genetics , Carcinoma/metabolism , Carrier Proteins/genetics , Carrier Proteins/metabolism , Cells, Cultured , Citric Acid Cycle , DNA Helicases/genetics , DNA Helicases/metabolism , Female , Glucose/deficiency , Glutamine/deficiency , Humans , Intracellular Signaling Peptides and Proteins , Mechanistic Target of Rapamycin Complex 1 , Mice , Mice, Knockout , Monomeric GTP-Binding Proteins/metabolism , Multiprotein Complexes , Protein Binding , Protein Multimerization , Protein Transport , Ribosomal Protein S6 Kinases, 90-kDa/metabolism , Signal Transduction , Statistics, Nonparametric , TOR Serine-Threonine Kinases , Telomere-Binding Proteins/genetics , Telomere-Binding Proteins/metabolism , Tuberous Sclerosis Complex 1 Protein , Tuberous Sclerosis Complex 2 Protein , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolismABSTRACT
Cells must sense environmental conditions and adjust to maintain metabolic homeostasis and survive stress conditions; in this issue, Cam et al. (2010) show that the tumor suppressor kinase ATM is activated by hypoxia, phosphorylates and stabilizes HIF-1α, and inhibits mTORC1.
ABSTRACT
The mTORC1-signaling pathway integrates environmental conditions into distinct signals for cell growth by balancing anabolic and catabolic processes. Accordingly, energetic stress inhibits mTORC1 signaling predominantly through AMPK-dependent activation of TSC1/2. Thus, TSC1/2-/- cells are hypersensitive to glucose deprivation, and this has been linked to increased p53 translation and activation of apoptosis. Herein, we show that mTORC1 inhibition during glucose deprivation prevented not only the execution of death, but also induction of energetic stress. mTORC1 inhibition during glucose deprivation decreased AMPK activation and allowed ATP to remain high, which was both necessary and sufficient for protection. This effect was not due to increased catabolic activities such as autophagy, but rather exclusively due to decreased anabolic processes, reducing energy consumption. Specifically, TSC1/2-/- cells become highly dependent on glutamate dehydrogenase-dependent glutamine metabolism via the TCA cycle for survival. Therefore, mTORC1 inhibition during energetic stress is primarily to balance metabolic demand with supply.
Subject(s)
Glucose/metabolism , Transcription Factors/metabolism , Tumor Suppressor Proteins/deficiency , AMP-Activated Protein Kinase Kinases , Animals , Cells, Cultured , Protein Kinases/metabolism , Rats , Signal Transduction , Tuberous Sclerosis Complex 1 Protein , Tuberous Sclerosis Complex 2 Protein , Tumor Suppressor Proteins/metabolismABSTRACT
The PI3K-Akt-mTOR growth-regulating pathway is conserved from mammals to flies and hyperactivated in many cancers. Accordingly, rapamycin analogs, which are inhibitors of mTOR-Raptor signaling, have recently garnered much interest as potential therapeutic agents against cancer. However, due to the heterogeneity of tumors, prior knowledge of the genetic and biochemical background of cancer cells will be required for effective targeted therapy. Thus, the identification of biological markers against activated oncogenic pathways is needed. In the January issue of Nature Medicine, Thomas et al. identify the loss of VHL tumor suppressor gene as a potential determining factor in tumor sensitivity to rapamycin.
Subject(s)
Neoplasms/drug therapy , Neoplasms/metabolism , Oncogenes/genetics , Protein Kinases/metabolism , Sirolimus/pharmacology , Von Hippel-Lindau Tumor Suppressor Protein/metabolism , Animals , Class I Phosphatidylinositol 3-Kinases , Humans , Phosphatidylinositol 3-Kinases/metabolism , Signal Transduction/drug effects , Sirolimus/therapeutic use , TOR Serine-Threonine Kinases , Von Hippel-Lindau Tumor Suppressor Protein/geneticsABSTRACT
The Vpr protein of HIV-1 functions as a vital accessory gene by regulating various cellular functions, including cell differentiation, apoptosis, nuclear factor of kappaB (NF-kappaB) suppression and cell-cycle arrest of the host cell. Several reports have indicated that Vpr complexes with the glucocorticoid receptor (GR), but it remains unclear whether the GR pathway is required for Vpr to function. Here, we report that Vpr uses the GR pathway as a recruitment vehicle for the NF-kappaB co-activating protein, poly(ADP-ribose) polymerase-1 (PARP-1). The GR interaction with Vpr is both necessary and sufficient to facilitate this interaction by potentiating the formation of a Vpr-GR-PARP-1 complex. The recruitment of PARP-1 by the Vpr-GR complex prevents its nuclear localization, which is necessary for Vpr to suppress NF-kappaB. The association of GR with PARP-1 is not observed with steroid (glucocorticoid) treatment, indicating that the GR association with PARP-1 is a gain of function that is solely attributed to HIV-1 Vpr. These data provide important insights into Vpr biology and its role in HIV pathogenesis.
Subject(s)
Cell Nucleus/metabolism , Gene Products, vpr/physiology , Poly(ADP-ribose) Polymerases/metabolism , Receptors, Glucocorticoid/metabolism , Active Transport, Cell Nucleus , Animals , Antigens, Bacterial/pharmacology , Cell Line , Chlorocebus aethiops , Enterotoxins/pharmacology , Female , Gene Expression/drug effects , Gene Expression/genetics , Gene Products, vpr/metabolism , Gene Products, vpr/pharmacology , HIV Infections/metabolism , HIV Infections/physiopathology , HeLa Cells , Humans , I-kappa B Kinase/metabolism , I-kappa B Proteins/metabolism , Interleukin-1/blood , Interleukin-12/blood , Jurkat Cells , Lipopolysaccharides/pharmacology , Mice , Mice, Inbred BALB C , Mifepristone/pharmacology , Mutation/genetics , NF-KappaB Inhibitor alpha , NF-kappa B/genetics , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/genetics , Protein Binding/drug effects , Protein Interaction Mapping , RNA, Small Interfering/genetics , Receptors, Glucocorticoid/genetics , Transcription Factor RelA/metabolism , Transfection , Tumor Necrosis Factor-alpha/metabolism , Tumor Necrosis Factor-alpha/pharmacology , U937 Cells , vpr Gene Products, Human Immunodeficiency VirusABSTRACT
Recent evidence demonstrates that HIV-1 infection leads to the attenuation of cellular immune responses, which has been correlated with the increased expression of programmed death (PD)-1 on virus-specific CD8(+) T cells. PD-1 is induced upon T cell activation, and its prolonged expression facilitates CD8(+) T cell inhibitory signals when bound to its B7 family ligands, PD-ligand (L)1/2, which are expressed on APCs. Importantly, early reports demonstrated that blockade of the PD-1/PD-L interaction by Abs may help to counter the development of immune exhaustion driven by HIV viral persistence. To better understand the regulation of the PD-1 pathway during HIV infection, we examined the ability of the virus to induce PD-L expression on macrophages and dendritic cells. We found a direct relationship between the infection of APCs and the expression of PD-L1 in which virus-mediated upregulation induced a state of nonresponsiveness in uninfected HIV-specific T cells. Furthermore, this exhaustion phenotype was revitalized by the blockade of PD-L1, after which T cells regained their capacity for proliferation and the secretion of proinflammatory cytokines IFN-γ, IL-2, and IL-12 upon restimulation. In addition, we identify a critical role for the PI3K/serine-threonine kinase signaling pathway in PD-L1 upregulation of APCs by HIV, because inhibition of these intracellular signal transducer enzymes significantly reduced PD-L1 induction by infection. These data identify a novel mechanism by which HIV exploits the immunosuppressive PD-1 pathway and suggest a new role for virus-infected cells in the local corruption of immune responses required for viral suppression.
Subject(s)
Antigen-Presenting Cells/immunology , CD8-Positive T-Lymphocytes/immunology , HIV Infections/immunology , Lymphocyte Activation/immunology , Signal Transduction/immunology , Antigen-Presenting Cells/metabolism , Antigens, CD/biosynthesis , Antigens, CD/immunology , Apoptosis Regulatory Proteins/biosynthesis , Apoptosis Regulatory Proteins/immunology , Blotting, Western , CD8-Positive T-Lymphocytes/metabolism , Cell Separation , Enzyme Activation/immunology , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , HIV Infections/metabolism , HIV-1/immunology , Humans , Ligands , Phosphatidylinositol 3-Kinases/immunology , Phosphatidylinositol 3-Kinases/metabolism , Programmed Cell Death 1 Receptor , Protein Serine-Threonine Kinases/immunology , Protein Serine-Threonine Kinases/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Up-RegulationABSTRACT
The mammalian translational initiation machinery is a tightly controlled system that is composed of eukaryotic initiation factors, and which controls the recruitment of ribosomes to mediate cap-dependent translation. Accordingly, the mTORC1 complex functionally controls this cap-dependent translation machinery through the phosphorylation of its downstream substrates 4E-BPs and S6Ks. It is generally accepted that rapamycin, a specific inhibitor of mTORC1, is a potent translational repressor. Here we report the unexpected discovery that rapamycin's ability to regulate cap-dependent translation varies significantly among cell types. We show that this effect is mechanistically caused by rapamycin's differential effect on 4E-BP1 versus S6Ks. While rapamycin potently inhibits S6K activity throughout the duration of treatment, 4E-BP1 recovers in phosphorylation within 6 h despite initial inhibition (1-3 h). This reemerged 4E-BP1 phosphorylation is rapamycin-resistant but still requires mTOR, Raptor, and mTORC1's activity. Therefore, these results explain how cap-dependent translation can be maintained in the presence of rapamycin. In addition, we have also defined the condition by which rapamycin can control cap-dependent translation in various cell types. Finally, we show that mTOR catalytic inhibitors are effective inhibitors of the rapamycin-resistant phenotype.
Subject(s)
Carrier Proteins/antagonists & inhibitors , Gene Expression Regulation/drug effects , Phosphoproteins/antagonists & inhibitors , Protein Biosynthesis/drug effects , Ribosomal Protein S6 Kinases/antagonists & inhibitors , Sirolimus/pharmacology , Transcription Factors/antagonists & inhibitors , Adaptor Proteins, Signal Transducing , Animals , Carrier Proteins/metabolism , Cell Cycle Proteins , Eukaryotic Initiation Factors , Mice , Phosphoproteins/metabolism , Phosphorylation , Protein Biosynthesis/physiology , Ribosomal Protein S6 Kinases/metabolism , Transcription Factors/metabolismABSTRACT
Chronic viral infection is characterized by the functional impairment of virus-specific T-cell responses. Recent evidence has suggested that the inhibitory receptor programmed death 1 (PD-1) is specifically upregulated on antigen-specific T cells during various chronic viral infections. Indeed, it has been reported that human immunodeficiency virus (HIV)-specific T cells express elevated levels of PD-1 and that this expression correlates with the viral load and inversely with CD4(+) T-cell counts. More importantly, antibody blockade of the PD-1/PD-L1 pathway was sufficient to both increase and stimulate virus-specific T-cell proliferation and cytokine production. However, the mechanisms that mediate HIV-induced PD-1 upregulation are not known. Here, we provide evidence that the HIV type 1 (HIV-1) accessory protein Nef can transcriptionally induce the expression of PD-1 during infection in vitro. Nef-induced PD-1 upregulation requires its proline-rich motif and the activation of the downstream kinase p38. Further, inhibition of Nef activity by p38 MAPK inhibitor effectively blocked PD-1 upregulation, suggesting that p38 MAPK activation is an important initiating event in Nef-mediated PD-1 expression in HIV-1-infected cells. These data demonstrate an important signaling event of Nef in HIV-1 pathogenesis.
Subject(s)
Antigens, CD/genetics , Apoptosis Regulatory Proteins/genetics , nef Gene Products, Human Immunodeficiency Virus/physiology , p38 Mitogen-Activated Protein Kinases/physiology , Acquired Immunodeficiency Syndrome/metabolism , Antigens, CD/biosynthesis , Apoptosis Regulatory Proteins/biosynthesis , CD4-Positive T-Lymphocytes/metabolism , Cells, Cultured , Gene Expression Regulation , Humans , Programmed Cell Death 1 Receptor , Up-RegulationABSTRACT
OBJECTIVE: To analyze a novel compound, which inhibits serine-threonine protein kinase p38, for its possible bioactivity against HIV-1 infection. METHODS: Proteins involved in cellular signal transduction pathways represent a novel class of host therapeutic targets for infectious diseases. In this regard the serine/threonine kinase p38 MAPK, a member of the mitogen-activated protein (MAP) kinase superfamily of signal transduction molecules may play an important role in HIV-1 infection. We analyzed the ability of this compound (RWJ67657) to inhibit HIV replication in primary T cells and monocytes. Cellular expression of phospho-p38MAPK was studied by Western blot analysis. Blockade of HIV infection induced apoptosis was measured by Annexin V staining. RESULTS: p38 inhibitor RWJ67657 was effective in inhibiting HIV-1 replication in both T-cell and monocyte cell lines, irrespective of the coreceptor used by the virus for entry into the cell. Importantly, both reverse transcriptase and protease resistant escape mutant viruses were effectively suppressed by RWJ67657. In addition, the tested compounds block HIV-induced T-cell apoptosis, a critical means of T-cell depletion linked to AIDS progression. CONCLUSION: Several steps in the HIV-1 virus life cycle appear to depend on cellular activation, including activation of the p38 pathway. Without activation virus replication is thought to be blocked due to incomplete reverse transcription and a lack of proviral DNA integration. The data collectively illustrate that inhibition of the p38 pathway can affect HIV-1 replication. Interruption of HIV infection by p38 inhibitors underscores the value of exploring antiviral drugs that target host cellular proteins.
Subject(s)
HIV-1/physiology , Imidazoles/pharmacology , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Pyridines/pharmacology , T-Lymphocytes/virology , Virus Replication/drug effects , Analysis of Variance , Annexin A5/analysis , Apoptosis , Biomarkers/analysis , Blotting, Western/methods , Cell Line , Drug Resistance, Viral , HIV-1/drug effects , Humans , Jurkat Cells , Mitogen-Activated Protein Kinases/metabolism , Monocytes/enzymology , Monocytes/pathology , Monocytes/virology , Phosphorylation , T-Lymphocytes/enzymology , T-Lymphocytes/pathology , U937 Cells , p38 Mitogen-Activated Protein KinasesABSTRACT
New and effective approaches for inflammatory diseases based on novel mechanisms of action are needed. One potential source of anti-inflammatory drugs exists among viruses. Viruses have evolved to infect, replicate within, and kill human cells through diverse mechanisms. They accomplish this fact by finding ways to out with the host's complex immune machinery. It is possible that the viral proteins and pathways involved in the downregulation of host immune function during infection can be exploited as a therapeutic in diseases that result in the overactivity of the immune system. Indeed, the human immunodeficiency virus type 1 (HIV-1) protein, Vpr, affects cells in a number of ways that may prove useful for exploitation for the treatment of inflammatory diseases. Vpr has effects on T-cell proliferation, cytokine production, chemokine production, and Nuclear Factor kappa B (NF-kappaB)-mediated transcription. Importantly, it has been observed that Vpr downregulates NF-kappaB and the production of pro-inflammatory cytokines such as TNF-alpha, and IL-12. These activities are worthy of further examination for control of hyperinflammatory and hyperproliferative conditions.
Subject(s)
Down-Regulation , Gene Products, vpr/therapeutic use , HIV-1/physiology , Inflammation/therapy , NF-kappa B/metabolism , Chemokines/metabolism , Gene Products, vpr/metabolism , Gene Products, vpr/physiology , Humans , Interleukin-12/metabolism , Models, Biological , T-Lymphocytes/metabolism , Tumor Necrosis Factor-alpha/metabolism , vpr Gene Products, Human Immunodeficiency VirusABSTRACT
Cancers can adapt several evasive functions including apoptosis evasion, self-sufficiency in growth signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless replication potential, tissue invasion and metastasis. The invariable hurdle for development of therapies against such aberrant conditions requires both selective and potent cytotoxicity. Analysis of HIV-1 Vpr's apoptotic and anti-proliferative activity have revealed potentially important implications for cancer therapy. Accordingly, we have reviewed the properties of Vpr that will likely contribute to its efficacious function as an anti-tumor agent. Among these are its ability to induce cell cycle arrest, inhibit inflammation, provoke p53 independent apoptosis, and selective killing of rapidly dividing cells.
Subject(s)
Apoptosis/physiology , Gene Products, vpr/physiology , Neoplasms/therapy , Apoptosis/genetics , Cell Line, Tumor , Cell Proliferation , Gene Products, vpr/genetics , Humans , Neoplasms/genetics , Neoplasms/physiopathology , Tumor Suppressor Protein p53/physiologySubject(s)
Cancer Vaccines , Neoplasms/therapy , Vaccines, DNA , Animals , Antigens, Neoplasm/immunology , Humans , Neoplasms/immunologyABSTRACT
The recent outbreaks of the H5N1 and H1N1 pandemic influenza have highlighted the importance of developing fast, effective therapeutic strategies to prevent and/or limit the spread of future influenza outbreaks. Although current vaccines against influenza are generally effective, several limitations, including those associated with the amount of available vaccine, the time to vaccine production and vaccine efficacy, may encumber a mass vaccination strategy and effective targeting against future outbreaks. This feature review discusses the prospects of SynCon-derived DNA vaccines against influenza; such vaccines are expected to be effective at targeting many currently circulating influenza virus strains, as well as potentially targeting strains that may be associated with future outbreaks. Because of advantages associated with safety, time to production and ease of production, as well as the generation of more effective immune responses, influenza DNA vaccines provide a promising potential solution to a global medical concern.
Subject(s)
Influenza Vaccines/immunology , Influenza Vaccines/pharmacology , Influenza, Human , Pandemics/economics , Vaccines, DNA/immunology , Vaccines, DNA/pharmacology , Animals , Birds , DNA/immunology , Disease Outbreaks/economics , Disease Outbreaks/prevention & control , Humans , Influenza A Virus, H1N1 Subtype/immunology , Influenza A Virus, H5N1 Subtype/immunology , Influenza in Birds/epidemiology , Influenza in Birds/immunology , Influenza, Human/economics , Influenza, Human/epidemiology , Influenza, Human/immunology , Influenza, Human/prevention & control , Pandemics/prevention & control , Vaccines, DNA/administration & dosageABSTRACT
The mTORC1 signaling pathway is a critical regulator of cell growth and is hyper activated in many different cancers. Rapamycin, an allosteric inhibitor of mTORC1, has been approved for treatment against renal cell carcinomas and is being evaluated for other cancers. Mechanistically, mTORC1 controls cell growth in part through its two well-characterized substrates S6K1 and 4E-BP1. In this review, we discuss the implications of a recent finding that showed differential inhibition of S6K1 and 4E-BP1 by rapamycin, leading to cell-type-specific repression of cap-dependent translation. We discuss potential mechanisms for this effect, and propose that mTOR-specific kinase inhibitors, instead of rapamycin, should be considered for mTOR-targeted cancer therapy.
Subject(s)
Drug Resistance, Neoplasm/physiology , Neoplasms/metabolism , Protein Kinases/metabolism , Sirolimus/metabolism , Transcription Factors/metabolism , Adaptor Proteins, Signal Transducing/metabolism , Animals , Cell Cycle Proteins , Gene Expression Regulation, Neoplastic , Humans , Mechanistic Target of Rapamycin Complex 1 , Multiprotein Complexes , Neoplasms/drug therapy , Neoplasms/physiopathology , Phosphoproteins/metabolism , Proteins , Ribosomal Protein S6 Kinases/metabolism , Signal Transduction/physiology , Substrate Specificity , TOR Serine-Threonine Kinases , Transcription Factors/antagonists & inhibitors , Transcription Factors/geneticsABSTRACT
The HIV-1 Vpr protein is a viral accessory protein that plays a number of important roles during HIV infection. The activities of Vpr are numerous and include the induction of apoptosis, the modulation of cell cycle arrest, as well as control of viral transcription. Study of HIV clones lacking Vpr in vitro and analysis of HIV variants isolated from long-term nonprogressors in vivo highlight the importance of Vpr for viral replication as well as immune suppression and cell death. Vpr may therefore be considered among the most important accessory proteins encoded by HIV.
Subject(s)
HIV-1/physiology , Virus Replication , vpr Gene Products, Human Immunodeficiency Virus/physiology , HIV-1/immunology , Humans , Immune ToleranceABSTRACT
Peptides that are capable of traversing the cell membrane, via protein transduction domains (PTDs), are attractive either directly as drugs or indirectly as carriers for the delivery of therapeutic molecules. For example, an HIV-1 Tat derived peptide has successfully delivered a large variety of "cargoes" including proteins, peptides and nucleic acids into cells when conjugate to the PTD. There also exists other naturally occurring membrane permeable peptides which have potential as PTDs. Specifically, one of the accessory proteins of HIV (viral protein R; i.e., Vpr), which is important in controlling viral pathogenesis, possesses cell transduction domain characteristics. Related to these characteristics, Vpr has also been demonstrated to induce cell cycle arrest and host/target cell apoptosis, suggesting a potential anti-cancer activity for this protein. In this report we assessed the ability of Vpr protein or peptides, with or without conjugation to a PTD, to mediate anti-cancer activity against several tumor cell lines. Specifically, several Vpr peptides spanning carboxy amino acids 65-83 induced significant (i.e., greater than 50%) in vitro growth inhibition/toxicity of murine B16.F10 melanoma cells. Likewise, in in vitro experiments with other tumor cell lines, conjugation of Vpr to the Tat derived PTD and transfection of this construct into cells enhanced the induction of in vitro apoptosis by this protein when compared to the effects of transfection of cells with unconjugated Vpr. These results underscore the potential for Vpr based reagents as well as PTDs to enhance anti-tumor activity, and warrants further examination of Vpr protein and derived peptides as potential therapeutic agents against progressive cell proliferative diseases such as cancer.
Subject(s)
Antineoplastic Agents/pharmacology , Gene Products, vpr/metabolism , HIV-1/physiology , Peptides/pharmacology , Proteins/pharmacology , Animals , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Carcinoma/drug therapy , Cell Line, Tumor , Female , Gene Products, vpr/genetics , HIV-1/genetics , HeLa Cells , Humans , Leukemia, Monocytic, Acute/drug therapy , Male , Melanoma, Experimental/drug therapy , Neuroblastoma/drug therapy , Prostatic Neoplasms/drug therapy , Skin Neoplasms/drug therapy , Transduction, GeneticABSTRACT
The TSC1/2 tumor-suppressor complex controls protein synthesis through the regulation of mTOR. In this issue of Cell, Inoki et al. (2006) report that the kinases GSK3 and AMPK cooperate in the activation of TSC2 to inhibit mTOR activity. Surprisingly, the phosphorylation of TSC2 by GSK3 is markedly suppressed by Wnt signaling. This suggests that components of the mTOR pathway may be therapeutic targets for diseases linked to hyperactive Wnt signaling.